FR2803207B1 - Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes - Google Patents

Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes

Info

Publication number
FR2803207B1
FR2803207B1 FR9916780A FR9916780A FR2803207B1 FR 2803207 B1 FR2803207 B1 FR 2803207B1 FR 9916780 A FR9916780 A FR 9916780A FR 9916780 A FR9916780 A FR 9916780A FR 2803207 B1 FR2803207 B1 FR 2803207B1
Authority
FR
France
Prior art keywords
vector
treatment
nucleic acid
acid encoding
angiogenic factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9916780A
Other languages
English (en)
Other versions
FR2803207A1 (fr
Inventor
Marc Abitbol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9916780A priority Critical patent/FR2803207B1/fr
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to AU28574/01A priority patent/AU2857401A/en
Priority to AT00993688T priority patent/ATE303820T1/de
Priority to JP2001549683A priority patent/JP2004500369A/ja
Priority to DK00993688T priority patent/DK1246642T3/da
Priority to US10/169,180 priority patent/US20030170209A1/en
Priority to ES00993688T priority patent/ES2245656T3/es
Priority to PCT/FR2000/003653 priority patent/WO2001049316A2/fr
Priority to EP00993688A priority patent/EP1246642B1/fr
Priority to DE60022549T priority patent/DE60022549T2/de
Publication of FR2803207A1 publication Critical patent/FR2803207A1/fr
Application granted granted Critical
Publication of FR2803207B1 publication Critical patent/FR2803207B1/fr
Priority to US12/013,638 priority patent/US20080107714A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR9916780A 1999-12-30 1999-12-30 Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes Expired - Fee Related FR2803207B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR9916780A FR2803207B1 (fr) 1999-12-30 1999-12-30 Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
EP00993688A EP1246642B1 (fr) 1999-12-30 2000-12-21 Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
JP2001549683A JP2004500369A (ja) 1999-12-30 2000-12-21 角膜血管新生を治療するための抗血管形成因子をコードする核酸を含むベクターの使用
DK00993688T DK1246642T3 (da) 1999-12-30 2000-12-21 Anvendelse af en vektor, der omfatter en nukleinsyre, som koder for en antiangiogen faktor, til behandling af karnydannelser i hornhinden
US10/169,180 US20030170209A1 (en) 1999-12-30 2000-12-21 Use of a vector comprising a nucleic acid coding for an anti-angiogenic factor for treating corneal neovascularization
ES00993688T ES2245656T3 (es) 1999-12-30 2000-12-21 Utilizacion de un vector que comprende un acido nucleico que codifica un factor anti-angiogeno para el tratamiento de las neovascularizaciones de la cornea.
AU28574/01A AU2857401A (en) 1999-12-30 2000-12-21 Use of a vector comprising a nucleic acid coding for an anti-angiogenic factor for treating corneal neovascularization
AT00993688T ATE303820T1 (de) 1999-12-30 2000-12-21 Verwendung von einem für einem anti-angiogenen faktor codierenden vektor zur behandlung von vaskularisation der hornhaut
DE60022549T DE60022549T2 (de) 1999-12-30 2000-12-21 Verwendung von einem für einem anti-angiogenen faktor codierenden vektor zur behandlung von vaskularisation der hornhaut
PCT/FR2000/003653 WO2001049316A2 (fr) 1999-12-30 2000-12-21 Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
US12/013,638 US20080107714A1 (en) 1999-12-30 2008-01-14 Use of a vector comprising a nucleic acid encoding an anti-angiogenic factor for the treatment of corneal neovascularization

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9916780A FR2803207B1 (fr) 1999-12-30 1999-12-30 Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes

Publications (2)

Publication Number Publication Date
FR2803207A1 FR2803207A1 (fr) 2001-07-06
FR2803207B1 true FR2803207B1 (fr) 2004-04-30

Family

ID=9554089

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9916780A Expired - Fee Related FR2803207B1 (fr) 1999-12-30 1999-12-30 Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes

Country Status (2)

Country Link
US (1) US20030170209A1 (fr)
FR (1) FR2803207B1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122181B2 (en) * 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US9216106B2 (en) * 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20050208102A1 (en) * 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
WO2016171529A1 (fr) * 2015-04-24 2016-10-27 포항공과대학교 산학협력단 Lentilles de contact intelligentes et verres intelligents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710796A (en) * 1971-05-14 1973-01-16 C Neefe Corneal drug delivery method
US5800820A (en) * 1989-01-10 1998-09-01 Repligen Corporation Methods and compositions for treatment of angiogenic diseases
FR2702152B1 (fr) * 1993-03-03 1995-05-24 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.
US5827702A (en) * 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
FR2731014B1 (fr) * 1995-02-23 1997-03-28 Rhone Poulenc Rorer Sa Molecules d'adn, preparation et utilisation en therapie genique
US5801146A (en) * 1996-05-03 1998-09-01 Abbott Laboratories Compound and method for inhibiting angiogenesis
CA2313705A1 (fr) * 1997-12-08 1999-06-17 Beth Israel Deaconess Medical Center Restine et ses methodes d'utilisation

Also Published As

Publication number Publication date
FR2803207A1 (fr) 2001-07-06
US20030170209A1 (en) 2003-09-11

Similar Documents

Publication Publication Date Title
DZ3177A1 (fr) Copolymère comprenant l'acide isophtalique.
DE69903543D1 (de) Formulierungen zur behandlung von magen-speiseröhren reflux
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
DE69826730D1 (de) Konditionierungslösungen für die Pflege von harten Kontaktlinsen
FR2732357B1 (fr) Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
FR2831818B1 (fr) Composition oxydante pour le traitement des fibres keratiniques comprenant une silicone aminee particuliere
DE69318693D1 (de) Magnetischer Konditionierer zur Behandlung von Flüssigkeiten
FR2750862B1 (fr) Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
MA25411A1 (fr) Microorganismes attenues pour le traitement d'infection.
FR2663044B1 (fr) Appareil pour le traitement de surfaces.
MA26950A1 (fr) Nouveaux retinoides pour le traitement de l'emphyseme
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
FR2803207B1 (fr) Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
HUP0200841A2 (en) Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein
FR2736538B3 (fr) Cage intersomatique pour rachis lombaire
FR2764811B3 (fr) Appareil pour le traitement physique des yeux
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
FR2769469B1 (fr) Systeme a base d'un biocide et d'un silicone polyether et son utilisation pour la desinfection des surfaces dures
DZ3320A1 (fr) Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine
DZ2649A1 (fr) Association des principes actifs pour le traitement de la démence sénile du type alzheimer.
MA23837A1 (fr) Benzamides pour le traitement de degenerescenses neurologiques
FR2800614B1 (fr) Composition pour le traitement des infections des voies respiratoires
FR2818150B1 (fr) Composition pour le traitement d'objets destines a etre desinfectes
FR2741535B1 (fr) Nouvelles preparations pour la sphere bucco-pharyngee
DE60017174D1 (de) Rivastigmine zur behandlung von augenerkrankungen

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

ST Notification of lapse

Effective date: 20180831